MY171180A - Anti-hla-b*27 antibodies and uses thereof - Google Patents

Anti-hla-b*27 antibodies and uses thereof

Info

Publication number
MY171180A
MY171180A MYPI2014002668A MYPI2014002668A MY171180A MY 171180 A MY171180 A MY 171180A MY PI2014002668 A MYPI2014002668 A MY PI2014002668A MY PI2014002668 A MYPI2014002668 A MY PI2014002668A MY 171180 A MY171180 A MY 171180A
Authority
MY
Malaysia
Prior art keywords
hla
antibodies
present
binding
certain embodiments
Prior art date
Application number
MYPI2014002668A
Other languages
English (en)
Inventor
Andrew J Murphy
Ana Kostic
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MY171180A publication Critical patent/MY171180A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MYPI2014002668A 2012-04-02 2013-04-02 Anti-hla-b*27 antibodies and uses thereof MY171180A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618969P 2012-04-02 2012-04-02
US201361778703P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
MY171180A true MY171180A (en) 2019-09-30

Family

ID=48093122

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014002668A MY171180A (en) 2012-04-02 2013-04-02 Anti-hla-b*27 antibodies and uses thereof

Country Status (22)

Country Link
US (1) US9790273B2 (enExample)
EP (1) EP2834272B1 (enExample)
JP (1) JP6320993B2 (enExample)
KR (1) KR20150003256A (enExample)
CN (1) CN104169302A (enExample)
AR (1) AR090585A1 (enExample)
AU (1) AU2013243644C1 (enExample)
BR (1) BR112014024622A2 (enExample)
CA (1) CA2868907C (enExample)
CL (1) CL2014002631A1 (enExample)
CO (1) CO7121320A2 (enExample)
EA (1) EA201491827A1 (enExample)
HK (1) HK1207092A1 (enExample)
IL (2) IL234707A0 (enExample)
MX (1) MX365690B (enExample)
MY (1) MY171180A (enExample)
NZ (1) NZ700650A (enExample)
PH (1) PH12014502184A1 (enExample)
SG (2) SG11201405759UA (enExample)
TW (1) TWI619729B (enExample)
UY (1) UY34721A (enExample)
WO (1) WO2013152001A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
CA2879577C (en) 2012-07-27 2021-08-03 City Of Hope An mva vaccine for delivery of a ul128 complex and preventing cmv infection
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
EA201791366A1 (ru) * 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
DK3253407T3 (da) * 2015-02-04 2020-06-29 Univ Zuerich Brug af hla-b27-homodimere til kræftbehandling
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
CA2996299C (en) 2015-08-24 2022-09-27 University Of Cincinnati Methods and compositions for the detection of fc receptor binding activity of antibodies
EP3347045A4 (en) 2015-09-10 2019-08-28 City of Hope MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
CN108401431B (zh) * 2015-12-18 2022-01-25 中外制药株式会社 抗-c5抗体及使用方法
EA201891420A1 (ru) * 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CA3016752C (en) 2016-03-08 2024-09-17 Universitat Zurich Hla-b57 open conformers
CN109562126A (zh) 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CA3031605A1 (en) 2016-08-10 2018-02-15 Universitat Zurich Mhc class ia open conformers
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
CN110520145A (zh) * 2017-03-31 2019-11-29 阿尔玛生物医疗公司 Hla-b27相关炎性疾病的治疗方法及相关组合物
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
CN108486226B (zh) * 2018-04-01 2022-04-12 广东辉锦创兴生物医学科技有限公司 Hla-b27等位基因的检测试剂盒及其应用
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
CN111175490A (zh) * 2020-01-19 2020-05-19 泛肽生物科技(浙江)有限公司 一种定性检测hla-b27的试剂盒及其检测方法
CA3189755A1 (en) 2020-07-25 2022-02-03 Regeneron Pharmaceuticals, Inc. Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response
CN117321084A (zh) * 2021-04-07 2023-12-29 雷杰纳荣制药公司 用于治疗mhc-1-病变的组合物
WO2023064850A1 (en) * 2021-10-14 2023-04-20 Regeneron Pharmaceuticals, Inc. Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
WO2023220263A1 (en) * 2022-05-13 2023-11-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for modulating tcr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340610C (en) * 1985-08-16 1999-06-29 Karen A. Nelson Monoclonal antibody to polymorphic hla determinant-b27
US5369010A (en) 1985-08-16 1994-11-29 Genetic Systems Corporation Monoclonal antibody to polymorphic HLA determinant -B27
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2012047294A2 (en) * 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途

Also Published As

Publication number Publication date
AU2013243644A1 (en) 2014-10-23
AU2013243644C1 (en) 2018-05-10
AR090585A1 (es) 2014-11-26
CL2014002631A1 (es) 2015-01-16
EP2834272A2 (en) 2015-02-11
SG10201608136SA (en) 2016-11-29
EA201491827A1 (ru) 2015-03-31
SG11201405759UA (en) 2014-11-27
CN104169302A (zh) 2014-11-26
PH12014502184A1 (en) 2014-12-10
TW201343675A (zh) 2013-11-01
CO7121320A2 (es) 2014-11-20
CA2868907A1 (en) 2013-10-10
US20130259876A1 (en) 2013-10-03
WO2013152001A3 (en) 2013-12-27
TWI619729B (zh) 2018-04-01
MX365690B (es) 2019-06-11
IL256716A (en) 2018-03-29
AU2013243644B2 (en) 2018-02-08
KR20150003256A (ko) 2015-01-08
UY34721A (es) 2013-10-31
JP2015514110A (ja) 2015-05-18
IL234707A0 (en) 2014-11-30
US9790273B2 (en) 2017-10-17
EP2834272B1 (en) 2020-06-24
WO2013152001A2 (en) 2013-10-10
CA2868907C (en) 2022-01-04
NZ700650A (en) 2017-02-24
JP6320993B2 (ja) 2018-05-09
HK1207092A1 (en) 2016-01-22
MX2014011898A (es) 2014-11-12
BR112014024622A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
PH12014502184A1 (en) Anti-hla-b* 27 antibodies and uses thereof
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
HK1207654A1 (en) Modified antibody regions and uses thereof
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
EA201492101A1 (ru) Антитела против fcrn
MX2015006973A (es) Inmunoterapia con agentes de enlace.
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
MX357391B (es) Anticuerpos anti-erbb3 y usos de los mismos.
TN2012000366A1 (en) Anticoagulant antidotes
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
BR112015020516A2 (pt) composições e métodos para imunoterapia
SG195072A1 (en) Cd3-binding molecules capable of binding to human and non-human cd3
MY165273A (en) Anti-cd48 antibodies and uses thereof
PH12012500843A1 (en) Engineered anti-tslp antibody
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
AU2012323781A8 (en) Antibodies to CD1d
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12015501687A1 (en) Novel binding proteins from pcsk9
TN2013000388A1 (en) Anticoagulant antidotes
WO2015022077A8 (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
HK1216654A1 (zh) 使用離子交換色譜來控制高甘露糖糖型的水平的方法
HK1223374A1 (zh) 抗fviii抗体或其用途